LETTER TO SHAREHOLDERS

02 - INTERVIEW WITH THE CHIEF EXECUTIVE OFFICER
"THE STRONG FINANCIAL PERFORMANCE IN THE FIRST QUARTER, ALLOWS US TO CONFIRM OUR GUIDANCE FOR 2017"

04 - NEWS: DUPIXENT® APPROVED IN THE U.S. FOR ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

05 - NEWS: KEVZARA® APPROVED IN THE U.S. IN MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS

06 - ANNUAL GENERAL MEETING 2017: APPROVAL OF A DIVIDEND OF €2.96 PER SHARE, 23RD CONSECUTIVE INCREASE

07 - SHAREHOLDER RELATIONS: INDIVIDUAL SHAREHOLDERS COMMITTEE
MESSAGE
FROM THE CHAIRMAN

DEAR SHAREHOLDERS,

I would like to thank you for following the Sanofi General Meeting on May 10th. All the resolutions were adopted, in particular those continuing the progressive renewal of the Board of Directors. With the appointment of two new directors, the Board is largely independent (79%) and increasingly international and gender-balanced (43% women). Dr. Melanie Lee, Chief Scientific Officer of an interventional medicine company, began her career in biomedical research and has extensive experience in oncology research. This appointment strengthens the scientific expertise of the Board. Bernard Charlès, Vice-Chairman and Chief Executive Officer of Dassault Systèmes, brings his knowledge in the digital field, a major element of differentiation in the health sector in the years to come.

I would like to come back to the importance of digital in the healthcare sector. Beyond scientific innovation which is essential to the future of the company, we want to innovate in other aspects of our business. Digital innovation is essential because it will provide Sanofi, our patients, health professionals and healthcare systems with many opportunities including more effective research, faster clinical trials, better disease management and stronger pharmacovigilance.

Digitalization should enhance efficiency for all players of the healthcare system and help bridge the gap between the growing needs of populations and the limited public and private resources in all countries. With your support, we will address these challenges.

Thank you for your trust and continuing loyalty.

DIGITAL WILL BE A MAJOR ELEMENT OF DIFFERENTIATION IN THE HEALTHCARE SECTOR IN THE YEARS TO COME.

FIRST QUARTER 2017
RESULTS

INTERVIEW
WITH THE CHIEF EXECUTIVE OFFICER

Olivier Brandicourt, Chief Executive Officer
RESULTS REFLECT THE INTEGRATION OF BOEHRINGER INGELHEIM’S CONSUMER HEALTHCARE BUSINESS AND VACCINES IN EUROPE

First quarter 2017 results reflect the acquisition of the former Boehringer Ingelheim (B) Consumer Healthcare business and the disposal of the Animal Health business (completed in almost all countries). They also reflect the consolidation of European operations related to Sanofi vaccine portfolio, following the termination of the Sanofi Pasteur MSD joint venture with Merck at the end of December 2016. Thus, Sanofi’s sales were €8,648M in the first quarter, an increase of 11.1% on a reported basis. As exchange rate movements had a favorable effect of 2.5 percentage points, sales were up 8.6% at constant exchange rates (CER) and up 3.5% at CER and constant structure (CS).

SALES GROWTH SUPPORTED BY SPECIALTY CARE, VACCINES AND EMERGING MARKETS

Sanofi Genzyme - Specialty Care delivered strong growth in all franchises in the first quarter. In particular, the Multiple Sclerosis franchise sales were up 32.4% at CER, reflecting the strong performance of Aubagio® and Lemtrada® in the U.S. and Europe.

Sanofi Pasteur - Vaccines growth accelerated in the first quarter due to the strong performance of pediatric combination vaccines, up 38.0% at CER and CS. It benefited from solid growth across geographies, in particular in the United States, due to the supply recovery of Pentacel®.

In Emerging Markets, sales reached €2,543M in the first quarter, an increase of 8.5% at CER and CS.

WHAT ARE THE HIGHLIGHTS FROM THE FIRST QUARTER 2017 RESULTS?

I am very satisfied with the strong financial performance in the first quarter, which allows us to confirm our guidance for 2017.

Sales benefited from structural changes with the integration of the Boehringer Ingelheim Consumer Healthcare portfolio and European vaccine businesses. Our Business EPS performance was also encouraging as we managed to offset the loss of the contribution of the Animal health business and a higher tax rate as a result of solid underlying sales momentum and the benefits from simplification of the organization.

Our diversified model continues to prove successful. The solid performance of Sanofi Genzyme and Sanofi Pasteur and to a lesser extent of Consumer Healthcare and General Medicines & Emerging Markets, supported growth despite the decline of the Diabetes & Cardiovascular business, which was impacted by lower insulin sales in the United States.

WHAT WAS THE CONTRIBUTION OF EMERGING MARKETS?

Emerging Markets sales were up 8.5% in the first quarter.1 It is important to note that all our franchises are growing in these markets, especially Oncology (+22.6%), Specialty Care (+16.3%), Diabetes & Cardiovascular (+12.3%) and Vaccines (+11.5%).1 I would like to highlight that the strongest performance in this region (+12.4%) comes from Asia, mainly due to the dynamic growth in China, the second largest pharmaceutical market after the United States, where our sales increased by 17%.1

WHAT CAN YOU TELL US ABOUT THE LAUNCHES OF DUPIXENT® AND KEVZARA® IN THE UNITED STATES?

These launches lay the foundation for our new Immunology franchise and represent a major milestone for patients and healthcare professionals. With Dupixent® which has been approved for the treatment of moderate-to-severe atopic dermatitis in adults, we have the opportunity to change the lives of patients who have been suffering from this devastating disease for many years without effective treatments.

As for Kevzara®, this innovative biological treatment represents a new therapeutic option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying anti rheumatic drugs.

This is an exciting time for Sanofi which is expected to continue with the anticipated approvals of these two innovative products in Europe.

1 - Growth rates are expressed at constant exchange rates (CER). Growth rates in brackets are expressed on a reported basis. For definitions of financial indicators, please consult the press release issued on April 28, 2017.
2 - Earnings per share. 3 - CS: constant structure: adjusted for BI CHC business, termination of SPMSD and others.
DUPIXENT® APPROVED IN THE U.S. FOR ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD)

At the end of March 2017, Sanofi and Regeneron announced the approval in the U.S. of Dupixent® (dupilumab), the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.

Dupixent® comes in a pre-filled syringe and can be self-administered as a subcutaneous injection every other week.

Thus, patients in the United States have access for the first time to a treatment that targets the system’s specific immunological dysfunction. So far, available treatments focused on managing symptoms.

A DEVASTATING DISEASE

Moderate-to-severe atopic dermatitis is a chronic inflammatory disease with symptoms characterized by rashes often covering much of the body. It can include intense, persistent itching and skin dryness, cracking, redness, crusting, and oozing. Itch is one of the most burdensome symptoms for patients and can be debilitating.

In clinical studies (LIBERTY AD program), Dupixent® significantly improved disease indicators in treated patients: skin lesions, itching, symptoms of anxiety and depression, and quality of life.

1 - Data on file.
2 - Survey of 505 American adults who self-reported being diagnosed with moderate-to-severe AD, conducted online by Harris Poll on behalf of Sanofi Genzyme and Regeneron.
KEVZARA® APPROVED IN THE U.S. IN MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS

Approximately 1.3 million Americans suffer from rheumatoid arthritis, with nearly 75% being women.

A NEW THERAPEUTIC OPTION

On May 22, 2017, the U.S Food and Drug Administration (FDA) approved Kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs, such as methotrexate.

Kevzara® may be used as monotherapy or in combination with conventional anti-rheumatic treatments once every two weeks as a subcutaneous injection.

A NOVEL MECHANISM OF ACTION

Rheumatoid arthritis is characterized by a disorder of the immune system that causes it to attack the tissues of the joints, causing inflammation, pain, and eventually joint damage and disability.

Kevzara® is a human monoclonal antibody that inhibits an organ-secreted protein that can contribute to the inflammation associated with the disease. In clinical trials, Kevzara® demonstrated statistically significant improvements in adult patients with rheumatoid arthritis by reducing signs and symptoms, improving physical function, and resulting in significantly less radiographic progression of structural damage of rheumatoid arthritis.

THE FOUNDATION OF A NEW FRANCHISE

Kevzara® and Dupixent®, developed in collaboration with Regeneron, lay the foundation of the new Immunology franchise.

Dupilumab is also studied for the treatment of other inflammatory allergic diseases. Phase 3 results in asthma are expected in the course of the year. Other indications evaluated include nasal polyposis, eosinophilic esophagitis, and food allergies.

REGULATORY MILESTONES IN EUROPE

KEVZARA®

At the end of April 2017, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the marketing authorization of Kevzara®, recommending its approval for use in adult patients with moderately to severely active rheumatoid arthritis.

INSULIN LISPRO BIOSIMILAR

On May 19, 2017, the CHMP has adopted a positive opinion for the marketing authorization of Insulin lispro Sanofi® (insulin lispro 100 Units/mL). CHMP recommended the use of Insulin lispro Sanofi® to treat adults and children who have diabetes and need insulin to keep their blood sugar level controlled, including those patients whose diabetes has just been diagnosed. This positive opinion is the company’s first major regulatory milestone for a biosimilar diabetes treatment.

The European Commission is expected to make a final decision on the two products in the coming months.

COLLABORATION

PREVENTION OF ILLNESSES ASSOCIATED WITH RESPIRATORY SYNCYTIAL VIRUS

On March 3, 2017, Sanofi Pasteur and MedImmune announced their agreement to develop and commercialize a monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV) illness in newborns and infants.

According to the Centers for Disease Control and Prevention, RSV is the most common cause of lower respiratory tract infections in children younger than 1 year of age in the United States and worldwide. RSV is considered to be the most important missing indication in the vaccination schedule of newborns.

EXECUTIVE COMMITTEE

BILL SIBOLD APPOINTED EXECUTIVE VICE PRESIDENT SANOFI GENZYME

Bill Sibold will join the Executive Committee as of July 1st, 2017. He is appointed Executive Vice President Sanofi Genzyme, succeeding David Meeker, who will leave the company at the end of June after a distinguished 23-year career with Genzyme and Sanofi.

Bill Sibold has been leading Sanofi Genzyme’s global organization Multiple Sclerosis, Oncology and Immunology since January 2016.
Sanofi’s Annual General Meeting was held on May 10, 2017 at the Palais des Congrès in Paris.
All resolutions submitted to the vote were adopted by shareholders.
More details, including detailed voting results and the video webcast of the event are available at: www.sanofi.com/AGM2017

Serge Weinberg, Chairman of the Board of Directors, opened the general meeting with the presentation of the developments of the company in 2016, a contrasting year that demonstrated the qualities of Sanofi both in its strategic positioning and in its operational ability to adapt. He also mentioned plans for the future, highlighting the importance of scientific innovation as well as digitalization, which may provide many opportunities for patients and all players of healthcare systems.

GOVERNANCE AND COMPENSATION POLICY

Serge Weinberg presented Sanofi’s governance. He notably reviewed the evolution of the composition of the Board as well as the activities of the Board and its committees in 2016.

Patrick Kron, Chairman of the Compensation Committee, presented this committee’s activities in more detail. He commented on the compensation policy and compensation elements of the Chairman of the Board and the Chief Executive Officer.

FINANCIAL PERFORMANCE

Jérôme Contamine, Executive Vice President and Chief Financial Officer, reminded those attending that 2016 was the first year of implementation of the strategic roadmap and a transition year with the evolution of the organization and the reshaping of the portfolio. Nevertheless, Sanofi’s solid financial performance in 2016 demonstrated the strength of its businesses throughout the world.

PERSPECTIVES

Olivier Brandicourt, Chief Executive Officer, shared the vision and mission of Sanofi in a changing environment before commenting on the achievements and prospects of the company’s global business units, focused on human health, and ranging from prevention to self-medication and prescription medicines. He also focused on the complex issue of Depakine and provided reassurance that Sanofi has always respected its obligations in the interest of patients. He underlined that patients are at the heart of Sanofi’s activities, whose mission is to find solutions to optimize their health management and improve their quality of life.

PROGRESS IN RESEARCH & DEVELOPMENT (R&D)

Elias Zerhouni, President Global R&D, presented the different phases of the R&D strategy. He pointed out that Sanofi had managed the shift towards biologics, which currently represent two thirds of the pipeline, and succeeded in increasing significantly the number of new product launches. He illustrated his point with the example of dupilumab, a product with great potential in multiple indications and also mentioned promising projects in oncology, rare diseases and diabetes.
RENEWAL OF THE BOARD OF DIRECTORS

Each year, the Board of Directors conducts a review to ensure that there is an appropriate balance in its composition and the composition of its Committees. In particular, the Board seeks to ensure gender balance and a broad diversity of backgrounds and countries of origin, reflecting Sanofi’s status as a diversified global business. The Board investigates and evaluates not only potential candidates, but also whether existing directors should seek reappointment. Above all, the Board seeks directors who show independence of mind and who are competent, dedicated and committed.

The General Meeting renewed Fabienne Lecorvaisier as Director and approved the appointment of Bernard Charlès and Melanie Lee as independent Directors, for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year 2020. The meeting also approved the amendment of the articles of association of the company allowing the appointment of two Directors representing employees at the Board of Directors.

Following the General Meeting, the new Board of Directors is comprised of 14 members, of whom six are women. A large majority of the Board’s Directors are independent (indicated by asterisks in the following list).

• Serge Weinberg*, Chairman of the Board of Directors
• Olivier Brandicourt, Chief Executive Officer
• Laurent Attal
• Robert Castaigne*
• Bernard Charlès*
• Claudie Haigneré*
• Patrick Kron*
• Fabienne Lecorvaisier*
• Melanie Lee*
• Suet-Fern Lee*
• Christian Mulliez
• Carole Piwnica*
• Diane Souza*
• Thomas Südhof*

NEW BOARD MEMBERS

These appointments continue the smooth and progressive implementation of the roadmap set by the Board of Directors to refresh its membership by:

• bringing more international CEO experience and more scientific expertise,
• as well as more non-French
• and female Directors, onto the Board.

Melanie Lee, PhD, CBE, is Chief Scientific Officer at BTG plc, a company which operates in interventional medicine in vascular disease, oncology and pulmonology.

Melanie Lee received an undergraduate degree in Biology from the University of York and then a Ph.D. at National Institute for Medical Research in London.

She worked as a molecular genetics postdoc, first at Imperial College London on yeast and then from 1985 with Sir Paul Nurse, a Nobel Prize winner, at the Imperial Cancer Research Fund’s Lincoln’s Inn Laboratories.

Bernard Charlès has served since May 2016 as Vice-Chairman and Chief Executive Officer of Dassault Systèmes, a world leader in 3D software.

The instigator of concepts including digital mock-up, product lifecycle management and 3DEXPERIENCE®, Bernard Charlès helped instill a culture of ongoing innovation to further consolidate Dassault Systèmes’ scientific capabilities and make science part of the company’s identity.

Bernard Charlès is a graduate of the École Normale Supérieure in Cachan. He is a doctor and holds an Aggregation in mechanics, specializing in the engineering of automation and computer science.
SHARE PERFORMANCE
IN PARIS

SANOFI SHARE PRICE TREND OVER 5 YEARS

On May 26, 2017, Sanofi had a market capitalization of more than €110bn.

NEW SHAREHOLDER HANDBOOK
NOW AVAILABLE

This handbook presents key figures for 2016 and the Group’s strategy. It provides information about Sanofi shares and how to manage them as well as practical information for shareholders. You will also find useful contact information and key shareholder events in 2017.

The handbook was distributed by e-mail to almost 50,000 shareholders. It is available on the SANOFI IR app and on the website: www.sanofi.com/shareholders.

If you want to receive the electronic version by e-mail or a printed copy by mail, please fill in the online subscription form: en.sanofi.com/subscription or call us: +33 (0) 800 075 876

Sanofi also publishes a Corporate Brochure “Sanofi 2017” and for the first time in 2017, an Integrated Report presenting in a synthetic manner the company’s strategy for creating short, mid- and long-term value (financial and extra-financial) for Sanofi and its stakeholders.

SANOFI – Shareholder Relations
54, rue La Boétie - 75008 Paris - France
Tel. Europe: +33 (0) 800 075 876
Toll-free tel. U.S.: +1 888 516 3002
Individual@shareholders@sanofi.com
www.sanofi.com/shareholders
Mobile app: SANOFI IR (available in the App Store and Google Play)

CALENDAR

- June 26, 2017: Shareholder meeting in Bordeaux
- July 31, 2017: Second quarter results 2017
- September 19, 2017: Shareholder meeting in Strasbourg
- October 2, 2017: Shareholder meeting in Lyon

SANOFI STOCK

- Euronext Paris, compartment A
  Member code: SAN
  ISIN code: FR 0000120578
- New York Stock Exchange
  Symbol: SNY
  CUSIP number: 80105N105000

SHAREHOLDER RELATIONS

Forward-looking statement:
This letter contains projections and other forward-looking statements that are not historical facts. Although the management of Sanofi believes that these projections and forward-looking statements, and their underlying assumptions, are reasonable as of the date of this letter, investors are cautioned that such projections, assumptions, intentions and forward-looking statements are subject to various risks and uncertainties (many of which are difficult to predict and generally beyond the control of Sanofi) that could cause actual results and developments to differ materially from those expressed or implied. These risks and uncertainties include those discussed elsewhere in this letter, as well as in the filings of Sanofi with the U.S. Securities and Exchange Commission (SEC) and the French Autorité des marchés financiers (AMF), notably under the caption “Risk Factors” in the company’s annual report on Form 20-F. Other than as required by applicable law, Sanofi does not undertake any obligation to update any statement that is not a historical fact.

The Letter to Shareholders is published by Sanofi Investor Relations / Shareholder Relations.


Design/production: SEITOSEI
Status: May 26, 2017